UBM fundamentals
An in-depth look to ULISSE BIOMED operating, investing, and financing activities
UBM free cash flow for H1 24 is -1.95 M EUR. For 2023, UBM free cash flow was -1.42 M EUR and operating cash flow was -1.39 M EUR.
H1 '20
H2 '20
H1 '21
H2 '21
H1 '22
H2 '22
H1 '23
H2 '23
H1 '24
−2.10 M
−1.40 M
−700.00 K
0.00
700.00 K
Cash from operating activities
Cash from investing activities
Cash from financing activities
Currency: EUR
H1 '20
Jun 2020
H2 '20
Dec 2020
H1 '21
Jun 2021
H2 '21
Dec 2021
H1 '22
Jun 2022
H2 '22
Dec 2022
H1 '23
Jun 2023
H2 '23
Dec 2023
H1 '24
Jun 2024
TTM
Cash from operating activitiesYoY growth
−597.60 K
+28.30%
−799.56 K
−114.44%
−585.86 K
+1.97%
−1.94 M
−143.00%
−2.53 M
Cash from investing activitiesYoY growth
−46.56 K
+92.57%
−90.53 K
+50.08%
−7.94 K
+82.95%
−20.00 K
+77.90%
−27.94 K
Cash from financing activitiesYoY growth
−26.00
−100.00%
1.70 K
−31.85%
−1.65 K
−6,257.69%
400.47 K
+23,526.73%
398.82 K
Free cash flowYoY growth
−599.62 K
+28.06%
−829.50 K
−84.68%
−587.85 K
+1.96%
−1.95 M
−134.84%
−2.54 M